The Use of Onexton in Moderate Acne Vulgaris for Patients With Skin of Color
Status:
Completed
Trial end date:
2018-02-28
Target enrollment:
Participant gender:
Summary
This is a single-center, open label pilot study. The study is comprised of 5 study visits;
Screening, Baseline, and Weeks 4, 8, and 16. All subjects will receive Onexton at Baseline
and be instructed to apply the gel once daily to the face. The investigators will evaluate
Investigator Global Assessment of acne (IGA), total lesion count, inflammatory lesion count,
non-inflammatory lesion count, Investigator Global Assessment of Post-Inflammatory
Hyperpigmentation and distribution of Post-Inflammatory Hyperpigmentation, adverse events and
concomitant medications.